Glucose-induced insulin secretion and α2-adrenergic receptor subtypes

Hiroshi Hirose, Hiroshi Maruyama, Katsuhiko Ito, Kazunori Koyama, Koichi Kido, Takao Saruta

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

α2-Adrenoceptor antagonists have been investigated in human in vivo studies as new oral antihyperglycemic agents. α2-Adrenoceptors are subdivided into α2A and α2B subtypes by using receptor-binding methods or cloning methods. This study was designed to determine the α2-adrenergic receptor subtype(s) involved in glucose-induced insulin and glucagon secretion from the isolated perfused rat pancreas at a glucose concentration of 16.7 mmol/L Both the α2A-preferentlal agonist oxymetazoline and the non-subtype-selective α2-agonist p-aminoclonidine, at concentrations above 10-9 mol/L, significantly inhibited glucose-induced insulin secretion (p < 0.05 and p < 0.01, respectively) and stimulated glucagon secretion from 10-7 mol/L, as compared with basal levels (p < 0.01, respectively). In contrast, the α1-selective agonist phenylephrine, at concentrations up to 10-6 mol/L, affected neither insulin nor glucagon secretion as compared with basal levels. Furthermore, the non-subtype-selective α2-antagonist rauwolscine, at concentrations above 10-6 mol/L, and the α2A-preferential antagonist WB-4101, at 10-5 mol/L, significantly antagonized the effects of 10-5 mol/L p-aminoclonidine on both insulin and glucagon secretion (p < 0.01 and p < 0.05, respectively). In contrast, neither the α1- and α2B-selective antagonist prazosin nor the α2B-preferential antagonist chlorpromazine, at concentrations up to 10-5 mol/L, antagonized the effects of p-aminoclonidine. These results suggest that α2A rather than α2B-adrenergic agonism inhibits glucose-induced insulin secretion and stimulates glucagon secretion in the isolated perfused rat pancreas.

Original languageEnglish
Pages (from-to)32-37
Number of pages6
JournalThe Journal of Laboratory and Clinical Medicine
Volume121
Issue number1
Publication statusPublished - 1993

Fingerprint

Glucagon
Adrenergic Receptors
Insulin
Glucose
Rats
Pancreas
Oxymetazoline
Yohimbine
Prazosin
Cloning
Chlorpromazine
Phenylephrine
Hypoglycemic Agents
Adrenergic Agents
Organism Cloning
apraclonidine

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Hirose, H., Maruyama, H., Ito, K., Koyama, K., Kido, K., & Saruta, T. (1993). Glucose-induced insulin secretion and α2-adrenergic receptor subtypes. The Journal of Laboratory and Clinical Medicine, 121(1), 32-37.

Glucose-induced insulin secretion and α2-adrenergic receptor subtypes. / Hirose, Hiroshi; Maruyama, Hiroshi; Ito, Katsuhiko; Koyama, Kazunori; Kido, Koichi; Saruta, Takao.

In: The Journal of Laboratory and Clinical Medicine, Vol. 121, No. 1, 1993, p. 32-37.

Research output: Contribution to journalArticle

Hirose, H, Maruyama, H, Ito, K, Koyama, K, Kido, K & Saruta, T 1993, 'Glucose-induced insulin secretion and α2-adrenergic receptor subtypes', The Journal of Laboratory and Clinical Medicine, vol. 121, no. 1, pp. 32-37.
Hirose, Hiroshi ; Maruyama, Hiroshi ; Ito, Katsuhiko ; Koyama, Kazunori ; Kido, Koichi ; Saruta, Takao. / Glucose-induced insulin secretion and α2-adrenergic receptor subtypes. In: The Journal of Laboratory and Clinical Medicine. 1993 ; Vol. 121, No. 1. pp. 32-37.
@article{5657cb65bbe644989b05f3dd82f2c0b3,
title = "Glucose-induced insulin secretion and α2-adrenergic receptor subtypes",
abstract = "α2-Adrenoceptor antagonists have been investigated in human in vivo studies as new oral antihyperglycemic agents. α2-Adrenoceptors are subdivided into α2A and α2B subtypes by using receptor-binding methods or cloning methods. This study was designed to determine the α2-adrenergic receptor subtype(s) involved in glucose-induced insulin and glucagon secretion from the isolated perfused rat pancreas at a glucose concentration of 16.7 mmol/L Both the α2A-preferentlal agonist oxymetazoline and the non-subtype-selective α2-agonist p-aminoclonidine, at concentrations above 10-9 mol/L, significantly inhibited glucose-induced insulin secretion (p < 0.05 and p < 0.01, respectively) and stimulated glucagon secretion from 10-7 mol/L, as compared with basal levels (p < 0.01, respectively). In contrast, the α1-selective agonist phenylephrine, at concentrations up to 10-6 mol/L, affected neither insulin nor glucagon secretion as compared with basal levels. Furthermore, the non-subtype-selective α2-antagonist rauwolscine, at concentrations above 10-6 mol/L, and the α2A-preferential antagonist WB-4101, at 10-5 mol/L, significantly antagonized the effects of 10-5 mol/L p-aminoclonidine on both insulin and glucagon secretion (p < 0.01 and p < 0.05, respectively). In contrast, neither the α1- and α2B-selective antagonist prazosin nor the α2B-preferential antagonist chlorpromazine, at concentrations up to 10-5 mol/L, antagonized the effects of p-aminoclonidine. These results suggest that α2A rather than α2B-adrenergic agonism inhibits glucose-induced insulin secretion and stimulates glucagon secretion in the isolated perfused rat pancreas.",
author = "Hiroshi Hirose and Hiroshi Maruyama and Katsuhiko Ito and Kazunori Koyama and Koichi Kido and Takao Saruta",
year = "1993",
language = "English",
volume = "121",
pages = "32--37",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Glucose-induced insulin secretion and α2-adrenergic receptor subtypes

AU - Hirose, Hiroshi

AU - Maruyama, Hiroshi

AU - Ito, Katsuhiko

AU - Koyama, Kazunori

AU - Kido, Koichi

AU - Saruta, Takao

PY - 1993

Y1 - 1993

N2 - α2-Adrenoceptor antagonists have been investigated in human in vivo studies as new oral antihyperglycemic agents. α2-Adrenoceptors are subdivided into α2A and α2B subtypes by using receptor-binding methods or cloning methods. This study was designed to determine the α2-adrenergic receptor subtype(s) involved in glucose-induced insulin and glucagon secretion from the isolated perfused rat pancreas at a glucose concentration of 16.7 mmol/L Both the α2A-preferentlal agonist oxymetazoline and the non-subtype-selective α2-agonist p-aminoclonidine, at concentrations above 10-9 mol/L, significantly inhibited glucose-induced insulin secretion (p < 0.05 and p < 0.01, respectively) and stimulated glucagon secretion from 10-7 mol/L, as compared with basal levels (p < 0.01, respectively). In contrast, the α1-selective agonist phenylephrine, at concentrations up to 10-6 mol/L, affected neither insulin nor glucagon secretion as compared with basal levels. Furthermore, the non-subtype-selective α2-antagonist rauwolscine, at concentrations above 10-6 mol/L, and the α2A-preferential antagonist WB-4101, at 10-5 mol/L, significantly antagonized the effects of 10-5 mol/L p-aminoclonidine on both insulin and glucagon secretion (p < 0.01 and p < 0.05, respectively). In contrast, neither the α1- and α2B-selective antagonist prazosin nor the α2B-preferential antagonist chlorpromazine, at concentrations up to 10-5 mol/L, antagonized the effects of p-aminoclonidine. These results suggest that α2A rather than α2B-adrenergic agonism inhibits glucose-induced insulin secretion and stimulates glucagon secretion in the isolated perfused rat pancreas.

AB - α2-Adrenoceptor antagonists have been investigated in human in vivo studies as new oral antihyperglycemic agents. α2-Adrenoceptors are subdivided into α2A and α2B subtypes by using receptor-binding methods or cloning methods. This study was designed to determine the α2-adrenergic receptor subtype(s) involved in glucose-induced insulin and glucagon secretion from the isolated perfused rat pancreas at a glucose concentration of 16.7 mmol/L Both the α2A-preferentlal agonist oxymetazoline and the non-subtype-selective α2-agonist p-aminoclonidine, at concentrations above 10-9 mol/L, significantly inhibited glucose-induced insulin secretion (p < 0.05 and p < 0.01, respectively) and stimulated glucagon secretion from 10-7 mol/L, as compared with basal levels (p < 0.01, respectively). In contrast, the α1-selective agonist phenylephrine, at concentrations up to 10-6 mol/L, affected neither insulin nor glucagon secretion as compared with basal levels. Furthermore, the non-subtype-selective α2-antagonist rauwolscine, at concentrations above 10-6 mol/L, and the α2A-preferential antagonist WB-4101, at 10-5 mol/L, significantly antagonized the effects of 10-5 mol/L p-aminoclonidine on both insulin and glucagon secretion (p < 0.01 and p < 0.05, respectively). In contrast, neither the α1- and α2B-selective antagonist prazosin nor the α2B-preferential antagonist chlorpromazine, at concentrations up to 10-5 mol/L, antagonized the effects of p-aminoclonidine. These results suggest that α2A rather than α2B-adrenergic agonism inhibits glucose-induced insulin secretion and stimulates glucagon secretion in the isolated perfused rat pancreas.

UR - http://www.scopus.com/inward/record.url?scp=0027471221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027471221&partnerID=8YFLogxK

M3 - Article

C2 - 8093889

AN - SCOPUS:0027471221

VL - 121

SP - 32

EP - 37

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 1

ER -